India’s Bharat Biotech will be producing part of the world’s only malaria vaccine that has been developed by Pharma major GSK, and was recently approved by WHO (World Health Organisation). However, it may take a couple of years before the vaccine is launched in the market for use. In January, this year, Hyderabad-based vaccine major announced that it entered a product transfer partnership with the pharma major GSK for its malaria vaccine, RTS, S/AS01E1.As part of this partnership, GSK would transfer RTS manufacturing technology to Bharat Biotech to produce the S antigen component of the malaria vaccine, and the license on all rights pertaining to it. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to Bharat Biotech.
New York City Human Rights Commission holds first public hearing on Sexual Harassment in over 40 years
NEW YORK CITY, NY (TIP): Building on the foundation of the City’s historic “women and workplace” hearings of the 1970s which catalyzed a national movement to recognize and address sexual harassment in the workplace, New […]